Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
NCT00234481
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
INDUSTRY
Sponsor class
Stopped
Study closed due to slow enrollment
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Interventions
DRUG:
XL844
Sponsor
Exelixis